FDA Approves Pancreatic Cancer Drug That Nearly Doubled Survival In Trial

The U.S. Food and Drug Administration (FDA) on Wednesday approved a groundbreaking new treatment for advanced pancreatic cancer that nearly doubled median survival in a clinical trial, marking what experts are calling one of the biggest advances against the deadly disease in decades.

The drug, daraxonrasib, which will be sold under the brand name Rasonque, ...